Stocks/AZTA/Filings & Earnings

AZTA SEC Filings, Earnings & Splits

Key events from SEC filings, earnings beat/miss history, stock split records, and share float data for AZTA.

What are AZTA's recent SEC filings?

8-K · OtherNov 10, 2026

Azenta, Inc. issued a press release announcing its financial results for the fiscal quarter and year ended September 30, 2026, furnished under Item 2.02 of Form 8-K.

View full filing details →
8-K · AcquisitionOct 30, 2026

Azenta acquired all outstanding capital stock of SynPlexity Inc., a DNA assembly technology company, and entered into exclusive licensing and supply agreements with Elegen Corp. to expand its GENEWIZ gene synthesis capabilities. Aggregate capital deployment for the Elegen arrangements is expected to range from approximately $32 million to $71 million.

View full filing details →
Perpetual license conversion option payment: $25.0M, Expected aggregate capital deployment range (low end): $32.0M, Expected aggregate capital deployment range (high end): $71.0M
8-K · OtherOct 7, 2026

Azenta's Board approved a restructuring plan within its Multiomics segment to consolidate its North American laboratory network, involving workforce reductions and closure of three lab sites. The company expects pre-tax charges of $11-13 million and annualized cost savings of approximately $11 million.

View full filing details →
Estimated aggregate pre-tax restructuring charges: $12.0M, Estimated asset impairment charges: $9.0M, Estimated employee severance and other restructuring charges: $3.0M, Estimated future cash expenditures: $7.0M, Expected annualized cost savings: $11.0M
8-K · Ceo ChangeSep 17, 2026

Azenta, Inc. appointed Dr. Martin D. Madaus as Interim President and CEO effective August 22, 2026, and on September 14, 2026, the Board approved his compensation package including a $600,000 base salary, a $600,000 performance bonus, and $1,200,000 in restricted stock units. Additionally, the company granted retention awards of restricted stock units to four named executive officers totaling $2,500,000.

View full filing details →
Interim CEO annual base salary: $600000, Interim CEO performance recognition bonus: $600000, Interim CEO restricted stock unit award value: $1.2M, CFO retention award value: $1.0M, General Counsel retention award value: $500000, CHRO retention award value: $500000, President, Multiomics retention award value: $500000
8-K · OtherSep 4, 2026

Azenta, Inc. announced the full repayment of a $35 million vendor loan related to the sale of B Medical Systems, receiving the entire $63 million purchase price in cash.

View full filing details →
Vendor loan principal: $35.0M, Total repayment amount including accrued interest: $35.4M, Total purchase price for B Medical: $63.0M
8-K · OtherAug 24, 2026

Azenta, Inc. filed an 8-K form with the SEC on August 24, 2026, but the filing text only contains directory listings and boilerplate SEC website navigation, not the actual event details.

View full filing details →

Has AZTA ever done a stock split?

No stock splits are recorded for AZTA.

What is AZTA's share float?

Public Float
$22.0M
Shares Outstanding
$43.8M
Free Float %
5017.3%

Get Real-Time AZTA Intelligence

SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.

Try SEPT X-Ray Free

More AZTA Research

AZTA FundamentalsAZTA AnalysisSEPT Academy
Share:XRedditFacebookLinkedIn
© SEPT Investing. Filing summaries are extracted automatically from SEC filings and may contain errors. Always verify with official SEC EDGAR filings. Trading involves risk.